LONDON, ONTARIO--(Marketwire - January 23, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE: COT), announced today that as a result of Company's decision to pursue a Phase 1B Health Canada clinical trial submission with its lead oncology compound COTI-2 it has strengthened its Scientific Advisory Committee with the appointment of Dr. Mark Vincent, a well respected clinical oncologist and clinical trials expert.
